U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 61 results

Status:
US Approved Rx (2006)
First approved in 1999

Class (Stereo):
CHEMICAL (ACHIRAL)



Cilostazol is a PDE3 inhibitor which is used for the treatment of intermittent claudication. The drug positively affects the platelet aggregation and may be used off-label as a measure to prevent coronary thrombosis/restenosis and stroke recurrence.
Status:
US Approved Rx (2005)
First approved in 1997

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Anagrelide is an orally active quinazinolone derivative that was originally developed as an antiplatelet drug. The drug inhibits cyclic nucleotide phosphodiesterase III (PDEIII) and phopholipase A2, which is thought to cause the side effects of vasod...
Status:
US Approved Rx (2023)
First marketed in 1921

Class (Stereo):
CHEMICAL (ACHIRAL)



Since its discovery as component of the tea leaf by Albert Kossel in 1888, the history of theophylline (CAS 58-55-9) has been a long and successful one. At the turn of the century, theophylline became less expensive due to chemical synthesis and was ...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


Pelrinone, a cardiotonic drug, is a phosphodiesterase III inhibitor that was studied in clinical trials phase II for the treatment of patients with heart failure.
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



NT-702 (parogrelil hydrochloride) is a novel phosphodiesterase 3 (PDE) inhibitor, and being developed for the treatment of intermittent claudication (IC) in patients with peripheral arterial disease. In Japan, Phase 2 studies are being conducted for ...
Status:
Investigational

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Sulrnazole (the former AR-L 115 BS) is a benzimidazole derivative with positive inotropic, positive chronotropic and vasodilator effects. Sulrnazole also has been shown to improve cardiac index and reduce pulmonary capillary wedge pressure without si...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Trequinsin is a potent PDE3 inhibitor that inhibits PDE4 and PDE2 at higher concentrations. Trequinsin can block platelet aggregation and also inhibit tissue factor expression in human endothelial cells. Trequinsin can enhance cellular cAMP content, ...
Status:
Investigational

Class (Stereo):
CHEMICAL (UNKNOWN)


Tolafentrine is phosphodiesterase 3/4 (PDE3/4) inhibitor. Treatment of endothelial cells with tolafentrine significantly decreased asymmetrical dimethylarginine-induced apoptosis via a cAMP/PKA-dependent pathway by induction of dimethylarginine dimet...
Status:
Investigational

Class (Stereo):
CHEMICAL (RACEMIC)


Motapizone is a pyridazinone derivative patented by pharmaceutical company Nattermann, A., und Cie. G.m.b.H. as an antithrombotic and hypotensive agent. Motapizone ats as a potent inhibitor of the isoenzyme phophodiesterase type III. In preclinical s...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


Revizinone (R-80122) is a selective phosphodiesterase (PDE) III inhibitor, developed for use in treatment of heart failure and ischaemic heart disorders. Revizinone showed positive inotropic and possibly moderate vasodilating properties in dogs, and ...